Mylan Launches First Generic Version of Teveten Tablets

Mylan Inc. MYL today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Eprosartan Mesylate Tablets, 400 mg and 600 mg. This product is the generic version of Abbott Laboratories' Teveten ^ Tablets, which are used to treat hypertension.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!